MilliporeSigma
All Photos(1)

Documents

20051

Supelco

ORBO 609 Amberlite XAD®-2 (20/50) 400/200 mg

W,W,W separators, O.D. × L 8 mm × 110 mm, pkg of 50 ea

Sign Into View Organizational & Contract Pricing

Synonym(s):
ORBO Amberlite XAD-2 Tube

material

W,W,W separators

Agency

NIOSH 2534,2537

product line

Amberlite
ORBO

composition

Bed A, 400 mg
Bed B, 200 mg

packaging

pkg of 50 ea

manufacturer/tradename

ORBO 609

technique(s)

active air sampling: suitable

O.D. × L

8 mm × 110 mm

matrix

XAD-2

particle size

20-50 mesh

application(s)

air monitoring
environmental
industrial hygiene

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
203492025820362
agency

NIOSH 2534,2537

agency

NIOSH 2546, OSHA 32,110

agency

NIOSH 2544,5506,5515,5800

agency

NIOSH 1453, OSHA 51

composition

Bed A, 400 mg , Bed B, 200 mg

composition

Bed A, 100 mg , Bed B, 50 mg

composition

Bed A, 100 mg , Bed B, 50 mg

composition

Bed A, 160 mg , Bed B, 80 mg

technique(s)

active air sampling: suitable

technique(s)

active air sampling: suitable

technique(s)

active air sampling: suitable

technique(s)

active air sampling: suitable

product line

Amberlite

product line

Amberlite, ORBO

product line

Amberlite, ORBO

product line

ORBO

packaging

pkg of 50 ea

packaging

pkg of 50 ea

packaging

pkg of 50 ea

packaging

pkg of 25 ea

General description

ORBO 609 Amberlite XAD®-2 (20/50), 400/200 mg sorbent tubes (W,W,W separators, O.D. × L 8 mm × 110 mm) contain two beds of the same selective adsorbent separated by glass wool or foam, for gas and vapor sampling. The dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.

Legal Information

Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Bjørn T Moe et al.
Anticancer research, 29(4), 1047-1052 (2009-05-06)
Endometrial hyperplasia is a precursor lesion of endometrial carcinoma. Clinical studies of endometrial hyperplasia have shown that levonorgestrel (LNG) is more therapeutically effective than medroxyprogesterone acetate (MPA). The present pharmacological in vitro study was performed to compare progestin effects on
A Orbo et al.
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 117(7), 972-976 (1997-03-10)
The development of female steroid hormone-related neoplasms such as gynaecologic and mammary cancers is influenced by hormones administered exogenously. Hormonal contraceptives and hormone replacement therapy both affect the risk of developing cancers in the endometrium, cervix, ovarium, and mammary glands.
K Flo et al.
Scandinavian journal of clinical and laboratory investigation, 55(8), 715-721 (1995-12-01)
Elevated extracellular cGMP levels have been observed in various clinical conditions, and the analyte has been proposed as a diagnostic marker of cardiovascular as well as malignant diseases. However, the use of extracellular cGMP as a pathophysiological marker requires detailed
Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
A Orbo et al.
Gynecologic oncology, 95(1), 82-88 (2004-09-24)
The purpose of the current study was to characterize the role of PTEN in malignant transformation and to evaluate the significance of mutated PTEN exons as prognostic markers in the carcinogenesis of endometrial hyperplasia. A comparison of PTEN mutations as

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service